JP2024099580A5 - - Google Patents

Download PDF

Info

Publication number
JP2024099580A5
JP2024099580A5 JP2024063143A JP2024063143A JP2024099580A5 JP 2024099580 A5 JP2024099580 A5 JP 2024099580A5 JP 2024063143 A JP2024063143 A JP 2024063143A JP 2024063143 A JP2024063143 A JP 2024063143A JP 2024099580 A5 JP2024099580 A5 JP 2024099580A5
Authority
JP
Japan
Prior art keywords
peptide
cancer
fragment
cell
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024063143A
Other languages
English (en)
Japanese (ja)
Other versions
JP7732024B2 (ja
JP2024099580A (ja
Filing date
Publication date
Priority claimed from DE102018107224.4A external-priority patent/DE102018107224A1/de
Application filed filed Critical
Publication of JP2024099580A publication Critical patent/JP2024099580A/ja
Priority to JP2024158604A priority Critical patent/JP2025000689A/ja
Publication of JP2024099580A5 publication Critical patent/JP2024099580A5/ja
Application granted granted Critical
Publication of JP7732024B2 publication Critical patent/JP7732024B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024063143A 2018-02-21 2024-04-10 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ Active JP7732024B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024158604A JP2025000689A (ja) 2018-02-21 2024-09-12 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862633325P 2018-02-21 2018-02-21
DE102018103944.1 2018-02-21
US62/633,325 2018-02-21
DE102018103944 2018-02-21
DE102018107224.4 2018-03-27
DE102018107224.4A DE102018107224A1 (de) 2018-02-21 2018-03-27 Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
PCT/EP2019/053168 WO2019162110A1 (en) 2018-02-21 2019-02-08 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
JP2020536952A JP7536642B2 (ja) 2018-02-21 2019-02-08 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020536952A Division JP7536642B2 (ja) 2018-02-21 2019-02-08 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024158604A Division JP2025000689A (ja) 2018-02-21 2024-09-12 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ

Publications (3)

Publication Number Publication Date
JP2024099580A JP2024099580A (ja) 2024-07-25
JP2024099580A5 true JP2024099580A5 (enExample) 2024-09-30
JP7732024B2 JP7732024B2 (ja) 2025-09-01

Family

ID=67482070

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020536952A Active JP7536642B2 (ja) 2018-02-21 2019-02-08 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ
JP2021199105A Active JP7384884B2 (ja) 2018-02-21 2021-12-08 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ
JP2024063143A Active JP7732024B2 (ja) 2018-02-21 2024-04-10 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ
JP2024158604A Pending JP2025000689A (ja) 2018-02-21 2024-09-12 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020536952A Active JP7536642B2 (ja) 2018-02-21 2019-02-08 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ
JP2021199105A Active JP7384884B2 (ja) 2018-02-21 2021-12-08 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024158604A Pending JP2025000689A (ja) 2018-02-21 2024-09-12 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ

Country Status (22)

Country Link
US (79) US10993962B2 (enExample)
EP (2) EP3755708A1 (enExample)
JP (4) JP7536642B2 (enExample)
KR (2) KR20200123134A (enExample)
CN (1) CN114040921A (enExample)
AU (5) AU2019225879B2 (enExample)
BR (2) BR112020014272A2 (enExample)
CA (1) CA3086916A1 (enExample)
CL (4) CL2020002123A1 (enExample)
CO (1) CO2020009869A2 (enExample)
CR (1) CR20200365A (enExample)
DE (1) DE102018107224A1 (enExample)
EA (2) EA202091754A1 (enExample)
IL (2) IL276845A (enExample)
MA (1) MA51890A (enExample)
MX (2) MX2020007767A (enExample)
MY (1) MY200985A (enExample)
PE (2) PE20211300A1 (enExample)
PH (1) PH12020551295A1 (enExample)
SG (2) SG11202006630RA (enExample)
TW (3) TW201936630A (enExample)
WO (1) WO2019162110A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
AU2020286756A1 (en) 2019-06-06 2022-01-27 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
WO2021041920A1 (en) * 2019-08-28 2021-03-04 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
KR102928901B1 (ko) * 2020-10-16 2026-02-23 애플 인크. 고주파 무선 통신 시스템에서 빠른 빔 추적을 위한 시스템 및 방법
CR20230295A (es) 2020-12-31 2023-07-27 Immatics Us Inc Polipéptidos cd8, composiciones y métodos de uso de estos
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
US20250136937A1 (en) * 2021-09-17 2025-05-01 Université de Montréal Novel tumor-specific antigens for colorectal cancer and uses thereof
CN119032273A (zh) 2022-01-25 2024-11-26 艾尔维缪恩公司 用于鉴定herv衍生的表位的新方法
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
KR20250018168A (ko) 2022-04-28 2025-02-04 이매틱스 유에스 인코포레이티드 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025211983A1 (ru) * 2024-04-05 2025-10-09 Общество с ограниченной ответственностью "Альбоген" Пептиды с противоопухолевой активностью

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US5759812A (en) * 1996-11-15 1998-06-02 Incyte Pharmaceuticals, Inc. Human selenium-binding protein
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO2000013699A1 (en) 1998-09-04 2000-03-16 Ludwig Institute For Cancer Research An antigenic peptide encoded by an alternative open reading frame of human macrophage colony-stimulating factor
EP1001022A1 (en) 1998-10-16 2000-05-17 Boehringer Ingelheim International GmbH CAMEL, an alternative translation product of the tumour antigen LAGE-1
US7504490B1 (en) 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
DE60029230T2 (de) 1999-09-10 2007-06-06 The University Of Sydney, Sydney Dipeptidyl-peptidasen
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1294748B1 (en) 2000-03-27 2010-06-30 Technion Research and Development of Foundation, Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
EP2322228B1 (en) 2000-06-05 2018-01-10 Altor BioScience Corporation T cell receptor fusion proteins and conjugates and methods of use thereof
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
EP2048159B1 (en) 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
DE102005041616B4 (de) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
DE602005020046D1 (de) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
EP2113253B1 (en) 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
EP2935325B1 (en) 2012-12-21 2018-02-07 Technische Universität Dresden Inhibitors of hairy and split 3 (hes3) as a new anti-cancer strategy
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI714869B (zh) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
CA3172682A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201520579D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
MA43477A1 (fr) 2016-04-21 2019-05-31 Immatics Biotechnologies Gmbh Immunothérapie contre le mélanome et d'autres cancers
TW202304970A (zh) * 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
CN111315769A (zh) * 2017-09-06 2020-06-19 加州理工学院 信号传导和抗原呈递双功能受体(sabr)
FR3070845B1 (fr) 2017-09-13 2021-07-30 Oreal Outil de mesure d'au moins une propriete d'une surface corporelle et procede de mesure associe
DE102018107224A1 (de) * 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten

Similar Documents

Publication Publication Date Title
JP2024041841A5 (enExample)
JP2021168652A5 (enExample)
JP2019511214A5 (enExample)
JP2021535900A5 (enExample)
JP2021514178A5 (enExample)
JP2019502360A5 (enExample)
JP2018529320A5 (enExample)
JP2019510465A5 (enExample)
JP2018510628A5 (enExample)
JP2020516681A5 (enExample)
JP2019506838A5 (enExample)
JP2020191862A5 (enExample)
JP2020182458A5 (enExample)
JP2020198875A5 (enExample)
JP2022502015A5 (enExample)
JP2021101700A5 (enExample)
RU2017137142A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2018518937A5 (enExample)
JP2018519243A5 (enExample)
JP2022502358A5 (enExample)
JP2018536383A5 (enExample)
JP2018520653A5 (enExample)
JP2021528046A5 (enExample)
JP2018509135A5 (enExample)
JP2018511321A5 (enExample)